AFYX Therapeutics is a private biopharmaceutical company focused on innovative approaches to treat mucosal diseases. The Company has developed the Rivelin patch, a breakthrough therapy for the treatment of mucosal diseases. Rivelin is designed to deliver a pharmaceutical drug uni-directionally to a mucosal surface using an occlusive, bio-adhesive and bio-degradable patch, with a long adhesion time and a high flexibility, conforming to the mucosal surface. AFYX's lead Rivelin patch product candidate seeks to treat the auto-immune, inflammatory disease oral lichen planus (OLP) through direct delivery of the drug clobetasol propionate. OLP may appear as lesions in the mouth that may cause burning, pain and other discomfort. OLP is considered an autoimmune disorder and requires regular monitoring given patients have increased risk of developing mouth cancer in the affected areas. No U.S. Food and Drug Administration (FDA) approved treatment exists, with today’s off-label treatment ranging from topical corticosteroids to laser ablation. It is estimated that OLP affects 1% to 2% of the population. Following successful results from a Phase 1b clinical study of the non-drug-loaded Rivelin patch in patients with OLP, AFYX has begun a Phase 2b clinical study of the clobetasol-loaded Rivelin patch in the United States and various countries in Europe. Shareholders include Sofinnova Ventures, Lundbeckfonden Emerge, Novo Seeds and Welfare Tech Invest.
